Renalytix AI PLC Director Dealing (0427L)
20 December 2018 - 5:28AM
UK Regulatory
TIDMRENX
RNS Number : 0427L
Renalytix AI PLC
19 December 2018
Renalytix AI plc
("RenalytixAI" or the "Company")
Director Dealing
The Company was informed that today, Christopher Mills, a
non-executive director, completed the purchase of 5,970 ordinary
shares of 0.25 pence each ("Ordinary Shares") in the Company at a
price of 103 pence per share.
Following this purchase, Mr Mills is interested in 9,196,400
Ordinary Shares representing 17.09% of the total voting rights in
the Company.
Enquiries:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
or
Tel: +1 646 397
3970
--------------------
N+1 Singer (Nominated Adviser & Broker) Tel: 020 7496 3000
--------------------
Aubrey Powell / James White / George Tzimas
(Corporate Finance)
--------------------
Tom Salvesen / Mia Gardner (Corporate Broking)
--------------------
Walbrook PR Limited Tel: 020 7933 8780
--------------------
or renalytix@walbrookpr.com
--------------------
Paul McManus / Lianne Cawthorne Mob: 07980 541 893
/ 07584 391 303
--------------------
Template for notification and public disclosure of transactions
by persons discharging managerial responsibilities and persons
closely associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Harwood Capital LLP (Harwood) as
investment manager to NASCIT
-------------------------------------- -------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status Christopher Mills, non-executive
director of the issuer and director
of North Altantic Smaller Companies
Investment Trust plc (NASCIT)
-------------------------------------- -------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------
a) Name Renalytix AI Plc
-------------------------------------- -------------------------------------------
b) LEI 213800NTOH3FK3WER551
-------------------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------
a) Description of the Ordinary shares of 0.25 pence each
financial instrument,
type of instrument
Identification code GB00BYWL4Y04
b) Nature of the transaction Purchase of shares
-------------------------------------- -------------------------------------------
c) Price(s) and volume(s)
-------------------- ------------------
Price(s) Volume(s)
-------------------- ------------------
103 pence 5,970
---------------------------------------------------------------- ------------------
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 19 December 2018
-------------------------------------- -------------------------------------------
f) Place of the transaction London Stock Exchange
-------------------------------------- -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFKCDBFBDDQBD
(END) Dow Jones Newswires
December 19, 2018 13:28 ET (18:28 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024
